The study demonstrated that the Omnipod automated glucose control algorithm performed well, was safe during the day and night for adults with type 1 diabetes, and was very effective at night with minimal hypoglycemia and excellent fasting glucose. These data were presented today at the 10th International Conference on Advanced Technologies & Treatments for Diabetes in Paris, France.